Table 11.
Summary of previous HIMAs showing the treatment conditions and TP53 mutant frequency in carcinogen-treated and spontaneously immortalised HUF clones.
| Carcinogen 1 | Treatment Conditions | Total TP53 Mutants | Total TP53 Mutations Detected | Mutant Frequency (Treated) 2 | Mutant Frequency (Untreated) 2 | Reference |
|---|---|---|---|---|---|---|
| BaP #1 | 1 µM; 4–6 days |
11 | 16 | 22.9% (11/48) |
12.5% (6/48) |
[11] |
| BaP #2 | 1 µM; 4–6 days |
14 | 18 | NI | NI | [25] |
| BPDE | 0.5 µM; 2 h |
16 4 | 20 4 | 15.7% 4 (16/102) |
3.7% 4 (2/54) |
[15] |
| 23 5 | 29 5 | 22.5% 5 (23/102) |
3.7% 5 (2/54) |
|||
| 3-NBA #1 | 2 µM; 5 days |
19 | 29 | 21.3% (19/89) |
10.4% (5/48) |
[38] |
| 3-NBA #2 | 1 µM; 48–96 h |
11 4 | 14 4 | 18.3% 4 (11/60) |
3.7% 4 (2/54) |
[13] |
| 11 5 | 12 5 | 18.3% 5 (11/60) |
3.7% 5 (2/54) |
|||
| N-OH-3-ABA | 2 µM; 5 days |
4 | 4 | 11.1% (4/36) |
10.4% (5/48) |
[38] |
| AAI #1 | 100 µM; 48 h |
5 | 6 | 20.8% (5/24) |
NI | [39] |
| AAI #2 | 50 µM; 48 h |
6 | 6 | 33.3% (6/18) |
NI | [12] |
| AAI #3 | 50 µM; 2/4 days |
21 | 25 | NI | NI | [40] |
| MNNG | 20 µM; 2 h |
11 | 13 | NI | NI | [40] |
| UV | 20 J/cm2 72 h |
5 | 7 | 25% (5/20) |
10% (2/20) |
[39] |
1 BaP = benzo[a]pyrene; BPDE = benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide; 3-NBA = 3-nitrobenzanthrone; N-OH-3-ABA = N-hydroxy-3-aminobenzanthrone; AAI = aristolochic acid I; MNNG = N-methyl-N-nitro-N-nitrosoguanidine; UV = ultraviolet radiation. 2 Brackets show the number of TP53 mutant clones versus the total clones analysed. 3 NI = not indicated. 4 Xpa+/+ HUFs. 5 Xpa−/− HUFs.